Sort   by:  
 Page size 
MOLM13 cells and patient-derived de novo AML cells with MLL1 rearrangement were treated with 100 nM of FHD-286 or 100 nM of AU15330, a dual BRG1/BRM protein degrader for 48 hours. The goal was to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitor...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD055994 | Pride
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (ATAC-Seq)
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (RNA-Seq human 16).
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (CUT&RUN human 8).
Targeting SWI/SNF ATPases in H3.3K27M Diffuse Intrinsic Pontine Gliomas [ATAC-Seq]
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma (ATAC-Seq human 8)
Targeting SWI/SNF ATPases in H3.3K27M Diffuse Intrinsic Pontine Gliomas [RNA-Seq]
Sort   by:  
 Page size